Skip to content

LBRX LBRX Total debt

Total debt at other companies

Alkermes logo
AlkermesALKS
$1.58B+2,034%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$5.59M
Alto Neuroscience logo
Alto NeuroscienceANRO
$20.88M-17.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.15M-98.1%
Opko Health logo
Opko HealthOPK
$52.78M-4.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $3.47M.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's total debt?
LBRX (LBRX) reported total debt of $3.47M in Q1 2026.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.